Dean, School of Basic Medical Sciences, University of
Benin, Prof. Isaiah Ibeh, on Tuesday announced the development of a new drug
that can cure HIV and AIDS.
Ibeh told the News Agency of Nigeria in Benin, the Edo State capital, that
the herbal drug had undergone “a series of successful tests.”
The University Public Relations
Officer, Harrison Osarenren, confirmed the story to our correspondent in a
telephone interview on Tuesday.
He said the professor had found the
solution. “The professor just developed a drug that can cure HIV/AIDS and it
has been tested. He has solution to AIDS.”
Ibeh told NAN, “We are at the
threshold of making history, in the sense that we seem to have with us
something that will permanently take care of what over time seems to have
defied all solutions.
“We are talking about the latest
discovery of an oral drug made from plants extraction in Nigeria for the
possible cure for the pandemic, HIV and AIDS virus.’’
According to him, research on the
project was started in 2010 and culminated in the development of “Deconcotion X
(DX)–Liquid or Bioclean 11 for the cure of HIV and AIDS.”
Ibeh added, “The existing retroviral
drugs are intervention drugs for the management of AIDS but our new discovery
is a possible cure. We have tried to look at the product first; its
toxicological analysis and discovered that it has a large safety margin.
“This means that if animals or human
beings are exposed to it, they will not suffer any serious harm at all from the
exposure.
“It also helped us to know the
quantity we can conveniently give to animals and will feel secure that nothing
untoward will happen.
“We have also done the
bacteriological analysis on it, after which we looked at its effect on the
virus and the result was quite revealing and refreshing.’’
Ibeh also said that the drug had been
exposed to series of medical examination both in Nigeria and in the USA. He
added that the drug had performed well on patients with the HIV virus and had
shown evidence of total restoration of damaged tissues.
He said, “The result showed an
increase in the body weight of the individual administered with DX.
“The body weight was statistically
significant when compared with the control group.’’ He said that further tests
were being conducted to determine “at what point will a patient become negative
after being administered the drug?”
He said, “This verification is
necessary because it is what is used to measure whether infection is still
there or not. So we need to know the siro-convention time.
“But preliminary results showed that
of the five latest patients orally administered with the drugs, our findings is
that up to seven months three of them were siro negative while two were still
faintly positive.’’ Ibeh appealed for support from the Federal Government and
relevant bodies to assist the university with relevant equipment to sustain the
research.
Source:
Punch
No comments:
Post a Comment